• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    TMC Expands Executive Team

    Peli BioThermal Opens Cold Chain Network Station in Southern California
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Purolite Expands Bioprocessing Production Capacity with New U.S. Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Biocair Partners with TrakCel to Improve Visibility in the Supply Chain

    SpectronRx, RLS Partner to Boost Radiopharmaceutical Pipeline and Supply Chain

    Serialization and the War on Counterfeit Drugs

    Traceability & 2D Barcodes
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Almac Group Global Workforce Hits 7,000 Employees

    Amarna Therapeutics Names Henk Streefkerk CEO

    Trinity Life Sciences Names Leslie Orne CEO
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Regulatory Affairs: Accelerating Drug Development Timelines

    Berkshire Sterile Secures Over $230,000 in Training Grants

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene International Ltd.

    INCOG BioPharma Services

    Federal Equipment Company

    U.S. Pharmacopeia (USP)

    TaiMed Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene International Ltd.

    INCOG BioPharma Services

    Federal Equipment Company

    U.S. Pharmacopeia (USP)

    TaiMed Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Cell and Gene Therapy is Coming of Age

    Outsourcing in the cell and gene therapy industry is booming—no longer considered just a “trend.”

    Cell and Gene Therapy is Coming of Age
    Heather White, Director of Strategic Partnerships, Center for Breakthrough Medicines05.03.23
    The enormous impact the pandemic had on the biopharma industry is unmistakable, as evidenced by the unprecedented investments that took place in the cell and gene therapy (CGT) space.

    In January 2022, the Milken Institute published a report, “Cell and Gene Therapies: Looking Ahead to 2022,”1 describing the growth of the CGT industry in 2021. In the U.S., 7 new therapies were approved for commercialization, a similar number were approved in Europe, and greater than 1,000 therapies were in development, with 75 expected to be approved in the U.S. by 2030.

    How accurate are these predictions?

    According to the Q4 2022 Quarterly Data Report2 by The American Society of Gene & Cell Therapy, 2 new gene therapies were approved in the U.S. in late 2022, bringing the worldwide total to 24. Currently, more than 2,000 clinical trials are ongoing globally. With approximately 10% of them in Phase III, it is likely that 75 therapies will be approved much sooner than 2030.

    The CGT industry has expanded rapidly, beginning a trend for innovator companies to outsource analytics, development, and/or the sophisticated manufacturing necessary in this nascent field. As the first quarter of 2023 concludes, it is more accurate to describe this “trend” as the new industry standard. In addition to an increased number of companies outsourcing their CGT development and manufacturing needs, many are shifting their service provider partnerships to much earlier in their developmental workflows. In a 2022 survey, 62% of respondents planned to outsource their viral vector manufacturing, whereas in 2023, that percentage has risen to 88%.

    In addition to the rapid growth of the industry, the current macroeconomic environment is also driving CGT companies to consider moving work to external service providers. Scrutiny of their cash positions and burn rates is steering companies towards outsourcing to maintain a positive financial position.

    Why is outsourcing necessary?

    The potential to revolutionize disease treatments makes CGT one of the fastest-growing segments of healthcare and is attracting massive investments from both the public and private sectors.

    A key challenge facing this industry is the high cost of developing and manufacturing these therapies, as they require specialized manufacturing facilities and expert personnel. These costs are often prohibitive for small and mid-sized companies, so they are turning to contract development and manufacturing organizations (CDMOs) as a solution. By employing this approach, companies have access to specialized facilities and expert personnel they wouldn’t otherwise have access to without a significant outlay of cash. By working with external partners that have already validated methods and platform processes, material and consumable costs can be trimmed and project budgets better controlled.

    Building facilities to manufacture at scale with highly trained experts is an enormous drain on resources. Fully equipped buildings range in price from $1,000 to $2,000 per square foot and can take between 18 months and five years to complete.  Sourcing, onboarding, training, and retaining the skilled talent required for the multiple complex processes is exceptionally difficult, as is procuring some of the equipment and consumables needed.

    Large biopharma has the resources to play in this advanced therapies arena, however, smaller biotechs and academia, where the majority of biotherapeutic development is taking place, do not have such deep pockets. With limited capital and the need to carefully manage their current funding, it is to a smaller firm’s financial advantage to outsource development and/or externalize manufacturing.

    In addition to the financial benefit, outsourcing allows companies to stay focused on their core competencies. Drug development is a complex process requiring extensive expertise. Outsourcing portions of the workflow allows companies to free up resources to remain concentrated on those activities at which they are most proficient.

    Most importantly, though, outsourcing typically results in a higher quality product. CDMOs have the expertise and experience necessary to manufacture CGTs at the highest standards and in consistent compliance with regulations.

    What functions should be outsourced?

    All pieces in the CGT workflow can now be outsourced and include:

    Manufacturing
    CGT manufacturing is a highly specialized process requiring extensive training and sophisticated instrumentation. Most companies choose to outsource as they lack the expertise and/or the financial resources to support the platforms.

    Quality control
    Quality control is an essential component of therapeutic development to ensure patient safety. Contract research organizations (CROs) have optimized and validated their platforms to maintain the highest standards with consistent and reproducible results.

    Regulatory compliance
    The CGT industry is highly regulated with strict compliance requirements for new product commercialization. These requirements, in addition to the constantly evolving regulatory landscape, make outsourcing regulatory support an efficient, cost-effective, and less risky solution as the outsourcing partners have departments focused on staying current with regulations.

    Market research
    Market research is critical for understanding  trends in the industry, the needs of patients and physicians, and developing marketing strategies. Outsourcing this function to a professional marketing research firm saves enormous time and expense for companies whose focus is developing new therapies.

    Should any functions remain in-house?

    Factors effecting which aspects of the CGT workflow should be done in-house versus externally are unique to each company and include:

    • A company’s existing capabilities;
    • The sustainability of maintaining in-house operations;
    • The availability of in-house talent;
    • The bandwidth of in-house resources; and
    • Access to capital markets.

    Flexibility is key

    Flexibility is essential in a CDMO partner. As the CGT field continues to evolve, a flexible CDMO partner with the ability to rapidly pivot in response to modifications in the scope or scale of the program, to adapt the program to revisions in the “end-to-end” services needed or adjust the business model to better align with the client’s specific financial situation is an attractive option. An outsourcing partner must be able to offer customized solutions tailored specifically to the client’s unique needs, such that the final deliverable meets their precise specifications.

    The ability to scale is essential when manufacturing CGT therapies. Scalable manufacturing capabilities, the capacity to scale-up based on required production volumes, is critically important. Having to tech transfer materials due to limited manufacturing volumes decreases the efficiency of the workflow, increases the turn-around time for the program, and exposes the material to contamination risks.

    Flexibility in service offerings is another valuable characteristic of an external partner. End-to-end service offerings integrated together at one site, reduces the risk of errors in change of custody, chain of identity, shipping, tracking, temperature controls, transportation, etc., that would be required if materials had to be transferred from facility to facility.

    And lastly, flexible business models are a strong indication that the potential CDMO partner is completely aligned with and committed to the success of the CGT organization. Instead of a “one-size-fits-all” approach, a CDMO willing to carve out financial and contractual terms designed for the individual needs of each client is one that is dedicated to the realization of the client’s mission to new life-saving therapies.

    Potential future trends

    There have always been geopolitical risks in relying on international supply chains; this was exacerbated by the recent pandemic, which highlighted the need for increased U.S.-based manufacturing. As a result, the past several years has witnessed a dramatic increase in domestic manufacturing to address the risk of dependency on an international supply chain. And as the CGT industry continues to expand, these efforts will become increasingly critical.

    The way therapies are manufactured and distributed will evolve, as well. For example, the future may see a more globalized approach to outsourcing as companies look to tap into international expertise and resources.  An implication of this trend includes a more competitive market, as companies source the best manufacturing and distribution partners worldwide. Another benefit of this evolution would be to increase the availability of therapies to patients globally.

    The industry will also see increased specialization in the CDMO market. The developing, manufacturing, and scaling-up of these therapies is an especially arduous process requiring deep expertise. As a result, companies looking to outsource CGT manufacturing will increasingly look for partners with specific specialization and experience in gene editing, viral vector development, process development and characterization, analytics, GMP manufacturing, and strong familiarity with regulatory and compliance guidance.

    As the CGT industry matures, CDMO outsourcing is expected to increase dramatically, playing an even more critical role in advanced therapy production. In addition, the IP landscape and quality control standards will become clearer as regulations are better defined, resulting in an even higher degree of expertise and level of capabilities offered in the outsourcing service provider marketplace. 

    References
    1. https://milkeninstitute.org/report/cell-gene-therapies-2022
    2. https://asgct.org/global/documents/asgct_citeline-q4-2022-report_final



    Heather White is a director of strategic partnerships at the Center for Breakthrough Medicines. In this role, she liaises with large pharma and biotech on a global scale to maintain a coordinated, holistic approach to business. Heather entered the cell and gene therapy space just shy of 1 year ago. Prior to CGT, she spent 9 years in the iPSC technology space. Here she worked with regenerative medicine companies, large pharma and biotech, and cell therapy companies to develop human cells to build organoids, for R&D purposes, and for developing cell therapies in the immunology space. 
    Related Searches
    • Biologics, Proteins, Vaccines
      Loading, Please Wait..
      Trending
      • SpectronRx, RLS Partner To Boost Radiopharmaceutical Pipeline And Supply Chain
      • Samsung Biologics Accelerates Timeline Of New Fifth Plant
      • Biopharma Layoffs In 1Q23
      • Veeva Business Consulting Expands With New R&D Services
      • CRO Industry Trends & Challenges
      Breaking News
      • EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
      • RK Pharma to Receive $200M Investment from PAG
      • Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
      • TMC Expands Executive Team
      • Peli BioThermal Opens Cold Chain Network Station in Southern California
      View Breaking News >
      CURRENT ISSUE

      May 2023

      • New Modalities Hog the Limelight
      • Cell and Gene Therapy is Coming of Age
      • Demand Surges for Cell and Gene Therapy Contract Manufacturing
      • Embracing a New Reality
      • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
      • Single-Use Technologies Enable Biologic Scaling
      • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
      • FTEs in Drug Discovery
      • Digital Transformation in Pharma
      • What is a Manufacturing Ecosystem and Why are They Growing?
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Sempera Organics and Alkemist Labs Announce Partnership for Mushroom Testing
      Nektium Expands International Distribution Network for Botanical Extracts
      Kemin Receives Positive EFSA Opinion for BetaVia Pure, its Beta-Glucan Ingredient
      Coatings World

      Latest Breaking News From Coatings World

      PPG’s New Paint for a New Start Initiative to Beautify Schools Worldwide with Colorful Makeovers
      Powder Technology, Inc. Announces New Electrical Coating
      Michelman Chosen as Inaugural Recipient of Innovation Research Interchange (IRI) Excellence Award
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Cue Health Nabs FDA's First De Novo Nod for an At-Home COVID Test
      ISO 13485:2016 Certification Granted to Boston BioProducts
      Paul Colvin Joins Ora Inc. as Chief Operating Officer
      Contract Pharma

      Latest Breaking News From Contract Pharma

      EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
      RK Pharma to Receive $200M Investment from PAG
      Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Estée Lauder Announces Second Edition of Beauty&You Brand Incubator Program
      GetHarley Raises $52 Million in Latest Funding Round
      Refillable Skincare Products Face Hurdles Despite Growing Sustainability Awareness
      Happi

      Latest Breaking News From Happi

      Carrière Frères Introduces Candle Refills as New Sustainability Initiative
      Gen Z Entrepreneur Introduces The Ashley Marie Collection for 4C Hair Types
      The Estée Lauder Companies Expands Beauty&You Competition for Indian Beauty Brands
      Ink World

      Latest Breaking News From Ink World

      Siegwerk’s Center of Excellence in France Receives Facelift
      Epson announces MakeTheSwitch Campaign
      Pigments Market to Reach $26,598 Million by 2022: AMR
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Mark Andy reports successful Low Migration Workshop
      Ryback and Ryback Consulting launches Machinery division
      TLMI launches 2023 award programs
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      The Honest Company to Exit Europe, Asia
      TechnoPlants to Exhibit at ITMA
      Andritz Buys 100% Stake in Dan-Web
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Orthobiologics Market to Top $10.3 Billion by 2030
      Artelon Granted U.S. FDA 510(k) Clearance for FlexBand, FlexPatch & FlexBand Plus
      Synergy Spine Solutions Completes Enrollment in IDE Clinical Trial
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      ASSA ABLOY Receives Clearance from Mexico for HHI Acquisition
      Christoph Ostermann Named Chairman of Heliatek‘s Advisory Board
      Flexible and Printed Electronics Represented at productronica 2023

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login